TerminatedPhase 4

Ultrasound-guided Injection for DeQuervain's

Stopped: not enough patient data

United States16 participantsStarted 2014-08-05

Plain-language summary

The investigators aim to perform a prospective study to evaluate the effectiveness of blind corticosteroid injections to US-guided injections for the treatment of de Quervain's disease. The results of the study will be used to validate current injection protocols or support the incorporation of ultrasonography to treat the disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pain with palpation at 1st dorsal compartment at wrist and positive Finkelstein's Test Exclusion Criteria: * Patients with evidence of osteoarthritis or degeneration of the wrist.

What they're measuring

DASH - "Disabilities of the Arm, Shoulder, and Hand" Score At Baseline, and Change From Baseline at 6-8 Weeks, 12-16 Weeks, and at 1 Year

Timeframe: Prior to injection (Dash #1), 6-8 weeks (Dash #2), 12-16 weeks (Dash #3), and 1 year (Dash #4) post-injection

Trial details

NCT IDNCT02038634

SponsorMedical College of Wisconsin

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-03-15

Results submitted2022-04-07

View on ClinicalTrials.gov More DeQuervain's Tenosynovitis trials